The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
HOPA 2018 | The role of PD-L1: is it accurate enough as a biomarker for immunotherapy response?
The expression of programmed death-ligand 1 (PD-L1) can be used as a clinical biomarker to determine the efficacy of immune checkpoint inhibitor treatment; however, there are many areas of uncertainty when it comes to PD-L1 testing. In this interview, recorded at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference held in Denver, CO, Jacob Kettle, PharmD, BCOP, of the University of Missouri Health Care, Columbia, MO, discusses the challenges of using PD-L1 levels as a determining factor in offering treatment to cancer patients.
